Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_2

50%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated2

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

completed125%

terminated250%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

NCT00421213

terminatedphase_2

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

NCT00423306

withdrawnphase_1

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

NCT01139359

completedphase_1

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

NCT01139346

Clinical Trials (4)

Showing 4 of 4 trials

NCT00421213Phase 2

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Terminated

NCT00423306Phase 2

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Terminated

NCT01139359Phase 1

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Withdrawn

NCT01139346Phase 1

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4